<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author><author><style face="normal" font="default" size="100%">Kantarjian, H.</style></author><author><style face="normal" font="default" size="100%">Weber, D.</style></author><author><style face="normal" font="default" size="100%">O'Brien, S.</style></author><author><style face="normal" font="default" size="100%">Estey, E.</style></author><author><style face="normal" font="default" size="100%">Delasalle, K.</style></author><author><style face="normal" font="default" size="100%">Rose, E.</style></author><author><style face="normal" font="default" size="100%">Cabanillas, F.</style></author><author><style face="normal" font="default" size="100%">Keating, M.</style></author><author><style face="normal" font="default" size="100%">Alexanian, R.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Clinical Oncology</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">1994</style></year><pub-dates><date><style  face="normal" font="default" size="100%">1994</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028173001&amp;partnerID=40&amp;md5=623e41ebed553144f5680076cf0a8cb9</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">12</style></volume><pages><style face="normal" font="default" size="100%">2694 - 2698</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Purpose: To assess the activity of 2-chlorodeoxyadenosine (2CdA) as primary therapy for patients with Waldenström's macroglobulinemia. Patients and Methods: 2CdA was given to 26 consecutive, previously untreated and symptomatic patients with Waldenström's macroglobulinemia. Two courses were administered to outpatients at a dose of 0.1 mg/ kg body weight per day for a 7-day continuous infusion using a portable pump through a central venous catheter. Responding patients were followed up without further therapy and were scheduled to receive two additional treatments with 2CdA on disease relapse. Results: Twenty-two of 26 patients responded to the 2CdA therapy (85%; 95% confidence interval [Cl], 65% to 96%), including three patients who achieved a complete response and 19 patients who had a partial response. Treatment was well tolerated, with no acute hematologic toxicity. A marked and sustained reduction of CD4+ lymphocytes occurred in all patients and may have contributed to a fatal infection with disseminated herpes simplex in one patient. With a median follow-up of 13 months, five patients have relapsed and all re-treated patients have responded again to 2CdA. Conclusion: 2CdA is highly active in previously untreated patients with Waldenström's macroglobulinemia. A limited program of treatment induced responses of good quality and long duration in more than 80% of patients. © 1994 by American Society of Clinical Oncology.</style></abstract><issue><style face="normal" font="default" size="100%">12</style></issue><notes><style face="normal" font="default" size="100%">Cited By :111Export Date: 21 February 2017</style></notes></record></records></xml>